EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages

Vallo Varik iD, Gang Wang iD, George Kritikos iD, Manuel Banzhaf iD, Emilien Drouot, Alexandra Koumoutsi iD, Françoise Van Bambeke iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01319-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Vallo Varik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium. Hauptthemen laut MEDLINE: Polymyxin B, Rifampin, Anti-Bacterial Agents, Gram-Negative Bacteria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Programming Initiative on Antimicrobial Resistance, EU Horizon Europe DIGIBIO project, China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotic-resistant bacteria, particularly the ESKAPE ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens, pose a major public health threat. Their ability to reside inside cells contributes to their persistence and resistance. Combining rifampicin with polymyxins is a much-discussed approach against multidrug-resistant Gram-negative bacterial infections. We therefore evaluated a combination of polymyxin B and rifampicin against Gram-negative clinical isolates in extracellular and intracellular in vitro models of infection. The combination was synergistic against intra- and extra-cellular forms of P. aeruginosa, A. baumannii, E. coli , and K. pneumoniae . This synergy was enhanced in an acidic environment resembling the host vacuole where intracellular bacteria reside. The combination remained synergistic against rifampicin and polymyxin B-resistant P. aeruginosa . To reveal the molecular underpinnings of the synergy, we used reverse genetics to identify and describe P. aeruginosa mutants more susceptible to the combination. They show altered membrane properties and more pronounced oxidative damage when exposed to the combination. This work sheds a new light on the mechanisms of the synergy between rifampicin and polymyxins, demonstrates its applicability to Gram-negative ESKAPE pathogens, including when residing intracellularly. Overall, the data suggest that repurposing rifampicin with polymyxin B can effectively target hard-to-eradicate intracellular bacteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyxin BRifampinAnti-Bacterial AgentsGram-Negative BacteriaDrug SynergismMicrobial Sensitivity TestsAcinetobacter baumanniiOxidative StressPseudomonas aeruginosaKlebsiella pneumoniaeCell MembraneDrug Resistance, Multiple, BacterialEscherichia coliStaphylococcus aureusEnterococcus faeciumHumansEnterobacter

Stichwörter der Autor:innen

ESKAPE pathogensGram-negative bacteriadrug repurposingdrug-drug interactionintracellular infectionpolymyxin Brifampicin

Substanzen

Polymyxin BRifampinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
  • European Molecular Biology Laboratory, Heidelberg, Germany.
  • Newcastle University Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.

ORCID-Profile: Vallo Varik, Gang Wang, George Kritikos, Manuel Banzhaf, Alexandra Koumoutsi, Françoise Van Bambeke

Förderung

  • Joint Programming Initiative on Antimicrobial Resistance
  • EU Horizon Europe DIGIBIO project
  • China Scholarship Council
  • UKRI Future Leaders Fellowship
  • EOS (Excellence of Science) program, Belgian FNRS-FRS
  • Belgian Fonds de la Recherche Scientifique

Zitieren

APA

Varik, V., Wang, G., Kritikos, G., Banzhaf, M., Drouot, E., Koumoutsi, A., & Van Bambeke, F. (2026). Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01319-25

Vancouver

Varik V, Wang G, Kritikos G, Banzhaf M, Drouot E, Koumoutsi A, et al. Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01319-25

BibTeX
@article{Varik2026,
  author = {Varik, Vallo and Wang, Gang and Kritikos, George and Banzhaf, Manuel and Drouot, Emilien and Koumoutsi, Alexandra and Van Bambeke, Françoise},
  title = {Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01319-25}
}
Kostenlos starten →